PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29465560
OWN - NLM
STAT- MEDLINE
DCOM- 20180302
LR  - 20180302
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 8
DP  - 2018 Feb
TI  - Olanzapine and haloperidol for the treatment of acute symptoms of mental
      disorders induced by amphetamine-type stimulants: A randomized controlled trial.
PG  - e9786
LID - 10.1097/MD.0000000000009786 [doi]
AB  - BACKGROUND: This study aimed to compare olanzapine and haloperidol efficacies in 
      the treatment of acute psychiatric symptoms due to amphetamine-type stimulants
      (ATSs). METHODS: The Zelen II design method was used; 124 patients with acute
      mental disorders due to amphetamine were randomly divided into olanzapine group
      (n = 63) and haloperidol group (n = 61). Then, a 4-week open-label medical
      therapy was performed. Clinical Global Impression Scale Item 2 was employed to
      evaluate the onset time; meanwhile, Brief Psychiatric Rating Scale (BPRS) was
      used at baseline and at posttreatment weeks 1, 2, and 4. Moreover, adverse
      reactions during the treatment were recorded. RESULTS: Onset time in the
      olanzapine group was significantly earlier than in the haloperidol group; BPRS
      scores in the olanzapine group were significantly lower than haloperidol group
      values at 1 and 2 weeks of treatment. The overall effective rates had no
      statistically significant difference. CONCLUSION: Short-term olanzapine and
      haloperidol treatments had equivalent efficacies in the treatment of acute
      symptoms of mental disorders due to ATSs; however, olanzapine administration
      resulted in relatively earlier disease onset, with less adverse reactions.
FAU - Xue, Xiaobin
AU  - Xue X
AD  - Department of Substance Abuse, Qingdao Mental Health Center, Qingdao.
FAU - Song, Yun
AU  - Song Y
AD  - Department of Neurology, Qianfoshan Hospital Affiliated of Shandong University,
      Jinan.
FAU - Yu, Xiaojie
AU  - Yu X
AD  - Department of Psychiatry Nursing, Qingdao Mental Health Center, Qingdao.
FAU - Fan, Qiang
AU  - Fan Q
AD  - Department of Substance Abuse, Ningbo An Kang Hospital, Fenghua.
FAU - Tang, Jiyou
AU  - Tang J
AD  - Department of Neurology, Qianfoshan Hospital Affiliated of Shandong University,
      Jinan.
FAU - Chen, Xu
AU  - Chen X
AD  - Department of Substance Abuse, Shandong Mental Health Center, Jinan, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Central Nervous System Stimulants)
RN  - 12794-10-4 (Benzodiazepines)
RN  - CK833KGX7E (Amphetamine)
RN  - J6292F8L3D (Haloperidol)
RN  - N7U69T4SZR (olanzapine)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Amphetamine/adverse effects
MH  - Amphetamine-Related Disorders/*drug therapy/psychology
MH  - Antipsychotic Agents/*administration & dosage
MH  - Benzodiazepines/*administration & dosage
MH  - Brief Psychiatric Rating Scale
MH  - Central Nervous System Stimulants/adverse effects
MH  - Female
MH  - Haloperidol/*administration & dosage
MH  - Humans
MH  - Male
MH  - Mental Disorders/chemically induced/*drug therapy
MH  - Research Design
MH  - Treatment Outcome
EDAT- 2018/02/22 06:00
MHDA- 2018/03/03 06:00
CRDT- 2018/02/22 06:00
PHST- 2018/02/22 06:00 [entrez]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2018/03/03 06:00 [medline]
AID - 10.1097/MD.0000000000009786 [doi]
AID - 00005792-201802230-00025 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Feb;97(8):e9786. doi: 10.1097/MD.0000000000009786.